Carl read the papersWhat it actually is
Exenatide is a synthetic version of exendin-4, a 39-amino-acid peptide isolated in 1992 from the venom of the Gila monster, a venomous lizard. Its sequence partly overlaps human GLP-1, enough to switch on the human GLP-1 receptor.
It was the first GLP-1 drug approved by the FDA, as twice-daily Byetta in 2005, nearly five years before liraglutide. A once-weekly version, Bydureon, followed in 2012. The FDA's drug database now marks the main Byetta listing, Bydureon, Bydureon BCise and the one US generic as discontinued, and the EU withdrew both brands on 1 January 2026 at the maker's request, for commercial reasons.
How it’s thought to work
- GLP-1 receptor activation — Boosts glucose-dependent insulin release from the pancreas, mostly when blood sugar is high.
- Less glucagon — Suppresses inappropriately high glucagon, without blocking the normal glucagon response to a low.
- Slower stomach — Slows gastric emptying, which flattens the after-meal spike and drives the nausea.
- Short half-life — About 2.4 hours for Byetta, hence two shots a day before meals. Bydureon was a separate slow-release weekly product.
What the research says
Lots of human data, mostly in diabetes, and mostly overtaken. EXSCEL put 14,752 people with type 2 diabetes on weekly exenatide 2 mg or placebo for a median 3.2 years: safe for the heart, but no significant drop in heart attacks, strokes or cardiovascular deaths (HR 0.91, p=0.06). The weekly form beat twice-daily Byetta on HbA1c (DURATION-1), then lost to semaglutide head to head (SUSTAIN 3: 1.9 kg vs 5.6 kg weight loss). In non-diabetic obesity it took off 5.1 kg against 1.6 kg on placebo over 24 weeks. Then Parkinson's: a 62-person trial in 2017 looked promising, but the 194-person phase 3 trial (Lancet 2025) found no benefit at 96 weeks.
- EXSCEL (n=14,752, median 3.2 years): heart-safe, but no significant cut in major cardiovascular events (HR 0.91).
- DURATION-1: weekly 2 mg beat 10 mcg twice daily on HbA1c (-1.9 vs -1.5 points at 30 weeks).
- SUSTAIN 3 (n=813, 56 weeks): semaglutide 1 mg beat exenatide ER 2 mg on HbA1c and weight (5.6 vs 1.9 kg).
- Parkinson's phase 3 (n=194, 96 weeks): no evidence it slows the disease.
Reported protocols
These are the doses the peptide community actually reports running (Reddit & forums), alongside published research — logged for education, not as a recommendation to use.
| Parameter | Commonly reported range |
|---|---|
| Label dose (Byetta) | 5 mcg twice daily within 60 minutes before the morning and evening meals; after 1 month may go to 10 mcg twice daily |
| Weekly form (Bydureon) | 2 mg once weekly, the dose used in DURATION-1 and EXSCEL |
| Timing rule | Never after a meal. Missed a dose? Skip it and take the next one on schedule |
| Route | Subcutaneous: thigh, abdomen or upper arm, rotating sites |
| Kidneys | Cleared mainly by the kidneys; exposure was 3.4 times higher in people on dialysis, and the label advises against it when kidney function is severely reduced |
| Community dose | Not established. The few dose mentions we found online just repeat the label (5 then 10 mcg twice daily) |
| Prescription | A prescription medicine, now off the US and EU markets |
Common use cases
| Goal | Community protocol notes |
|---|---|
| Type 2 diabetes | the approved use: 5 then 10 mcg twice daily, or 2 mg weekly |
| Weight loss | never approved for it; about 3.5 kg more than placebo over 24 weeks in one obesity trial |
| Parkinson's disease | tested in phase 3 and failed; not a use case |
Mixing it (reconstitution)
Freeze-dried peptides must be reconstituted with bacteriostatic water before they can be measured. Carl’s calculator turns “mg in the vial + ml of water + target dose” into “units on the syringe” — and tells you how long the vial lasts.
→ Open the Reconstitution Calculator
Injection & handling
Byetta was a pre-filled pen of solution, injected under the skin of the thigh, abdomen or upper arm in the hour before the two main meals, about 6 hours or more apart, and never after eating. The month at 5 mcg is there for your stomach. With insulin, it goes in as a separate injection and is never mixed in the same syringe. Bydureon was a separate weekly 2 mg product. With the licensed brands discontinued in the US and withdrawn in the EU, a vial sold as exenatide today is not the licensed product.
Stacks it appears in
- With insulin — An approved combination in type 2 diabetes, but the label warns about low blood sugar and says they must be separate injections, never mixed.
- With an amylin analogue — Amylin works on a separate appetite system, the logic behind CagriSema. We found no trial of exenatide with cagrilintide.
Sources
- FDA label: Byetta (DailyMed, Sep 2025)
- Drugs@FDA: NDA 021773 (Byetta)
- Knop et al., Exenatide: pharmacokinetics, clinical use, and future directions, Expert Opin Pharmacother 2017 (PMID 28085521)
- Drugs@FDA: NDA 022200 (Bydureon) and NDA 209210 (Bydureon BCise)
- Drugs@FDA: NDA 022341 (Victoza), for 'five years before liraglutide'
- EMA: Byetta, withdrawn
- EMA: Bydureon, withdrawn
- Eng et al., isolation of exendin-4 from Heloderma suspectum venom, J Biol Chem 1992 (PMID 1313797)
- Holman et al., EXSCEL, N Engl J Med 2017 (PMID 28910237)
- Drucker et al., DURATION-1, Lancet 2008 (PMID 18782641)
- Ahmann et al., SUSTAIN 3, Diabetes Care 2018 (PMID 29246950)
- Rosenstock et al., exenatide in non-diabetic obesity, Diabetes Care 2010 (PMID 20332357)
- Athauda et al., exenatide in Parkinson's, Lancet 2017 (PMID 28781108)
- Vijiaratnam et al., Exenatide-PD3 phase 3, Lancet 2025 (PMID 39919773)
- ClinicalTrials.gov NCT01144338 (EXSCEL)
- ClinicalTrials.gov NCT04232969 (Exenatide-PD3)
- SAHPRA: Peptide Products, Public Information (May 2026)
- WADA 2026 Prohibited List
